Rapamycin Holdings Changes Name to Emtora Biosciences, Hires New CEO...

02/26/19

Rapamycin Holdings Changes Name to Emtora Biosciences, Hires New CEO  Xconomy

San Antonio --- Rapamycin Holdings, a life sciences business working to commercialize a new formulation of an immunosuppressant as a prostate cancer drug,

[more]